VIP and myeloid sarcoma: These data, despite being obtained from animal observations, pinpoint the potential distinctive beneficial roles of the two neuropeptides’ receptors with respect to different pathological domains of MS [28,29], and warrant further investigations on VIP/PACAP receptor expression and distribution in the human MS brain.